Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by RalphRalphon Nov 08, 2020 4:03pm

156 Views

Post# 31859819

RE:RE:RE:RE:RE:Opinion

I'm familiar enough with biotech to know that this management team is weak. Contrast it to a company with effective management like OCUL and the difference becomes clear.

Can you think of many other clinical-stage biotech companies that diluted heavily to purchase a subsidiary company completely unrelated to their primary platform & mission? That's just one example of the company's poor management; it's not old news when the same people who have a track record of poor business execution remain in charge. As I said, the science side of things looks stellar; the business execution looks sub-par at best. If you'd like to provide examples of savvy business decisions made by this management team, please feel free.

Arbourmark wrote: Ralph,

My point is bringing up old news and continuously recirculating is of no benefit to the boards.

Your comment about believing in the science but stating management is not capable is interesting. One would think that it was management who advanced the drug through the various stages. Have you invested in early stage pharma in the past, if not it is a long process to get a drug through various trials and many fail regardless of the management.

I have no idea how long you have owned this stock but if you feel the company has weak management, why would you invest in it, as the science will not take the company to the finish line alone.